Last reviewed · How we verify

Westlake Pharmaceuticals (Hangzhou) Co., Ltd. — Portfolio Competitive Intelligence Brief

Westlake Pharmaceuticals (Hangzhou) Co., Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
WPV01 WPV01 phase 3 SARS-CoV-2 main protease inhibitor SARS-CoV-2 main protease Infectious Diseases

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Addpharma Inc. · 1 shared drug class
  2. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  3. Beijing Minhai Biotechnology Co., Ltd · 1 shared drug class
  4. Biota Scientific Management Pty Ltd · 1 shared drug class
  5. Cocrystal Pharma, Inc. · 1 shared drug class
  6. Ethris GmbH · 1 shared drug class
  7. IRCCS San Raffaele · 1 shared drug class
  8. Icahn School of Medicine at Mount Sinai · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Westlake Pharmaceuticals (Hangzhou) Co., Ltd.:

Cite this brief

Drug Landscape (2026). Westlake Pharmaceuticals (Hangzhou) Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/westlake-pharmaceuticals-hangzhou-co-ltd. Accessed 2026-05-16.

Related